Volume 29, No 8, Aug 2019

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 29 Issue 8, August 2019: 607-608

RESEARCH HIGHLIGHTS

AIF: an acquired metabolic liability in lung cancer

Brandon Faubert¹, Ralph J. DeBerardinis ^1,2,3,4 and John D. Minna ^5,6

¹ Children’s Medical Center Research Institute, Dallas, TX, USA; ²Department of Pediatrics, Dallas, TX, USA; ³Eugene McDermott Center for Human Growth and Development, Dallas, TX, USA; ⁴Howard Hughes Medical Institute, Dallas, TX, USA; ⁵Hamon Center for Therapeutic Oncology Research, Dallas, TX, USA and ⁶Department of Internal Medicine and Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Correspondence: Brandon Faubert (Brandon.Faubert@UTSouthwestern.edu) or Ralph J. DeBerardinis (Ralph.DeBerardinis@UTSouthwestern.edu) or John D. Minna(John.Minna@UTSouthwestern.edu)

Apoptosis-inducing factor has two roles: acting as an apoptosis effector and maintaining mitochondrial metabolism. A recent study uncouples these roles and finds that only the mitochondrial functions are required for tumorigenesis in mice.

https://doi.org/10.1038/s41422-019-0197-9

FULL TEXT | PDF

Browse 636